與「Javier Bachiller-Corral」相符的使用者個人學術檔案
 | Javier Bachiller CorralReumatologo. Servicio de Reumatologia. Hospital Ramon y Cajal. 在 salud.madrid.org 的電子郵件地址已通過驗證 被引用 2188 次 |
Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported …
…, ZS Wallace, S Al-Adely, J Bachiller-Corral… - Annals of the …, 2021 - ard.bmj.com
Objectives To determine factors associated with COVID-19-related death in people with
rheumatic diseases. Methods Physician-reported registry of adults with rheumatic disease and …
rheumatic diseases. Methods Physician-reported registry of adults with rheumatic disease and …
Influence of antisynthetase antibodies specificities on antisynthetase syndrome clinical spectrum time course
Antisynthetase syndrome (ASSD) is a rare clinical condition that is characterized by the
occurrence of a classic clinical triad, encompassing myositis, arthritis, and interstitial lung …
occurrence of a classic clinical triad, encompassing myositis, arthritis, and interstitial lung …
Garetosmab in fibrodysplasia ossificans progressiva: A randomized, double-blind, placebo-controlled phase 2 trial
…, J Tabarkiewicz, M Szczepanek, J Bachiller-Corral… - Nature medicine, 2023 - nature.com
Fibrodysplasia ossificans progressiva (FOP) is a rare disease characterized by heterotopic
ossification (HO) in connective tissues and painful flare-ups. In the phase 2 LUMINA-1 trial, …
ossification (HO) in connective tissues and painful flare-ups. In the phase 2 LUMINA-1 trial, …
High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive study
…, A Boteanu, J Bachiller-Corral… - Rheumatology …, 2020 - Springer
The objective of this study is to describe the characteristics and outcomes of rheumatic and
musculoskeletal disease (RMD) patients who were treated with rituximab and had suspected …
musculoskeletal disease (RMD) patients who were treated with rituximab and had suspected …
Clinical spectrum time course in anti Jo-1 positive antisynthetase syndrome: results from an international retrospective multicenter study
Anti Jo-1 antibodies are the main markers of the antisynthetase syndrome (ASSD), an
autoimmune disease clinically characterized by the occurrence of arthritis, myositis, and interstitial …
autoimmune disease clinically characterized by the occurrence of arthritis, myositis, and interstitial …
Risk of severe COVID-19 infection in patients with inflammatory rheumatic diseases
J Bachiller-Corral, A Boteanu… - The Journal of …, 2021 - jrheum.org
Objective. To describe the cohort of patients with inflammatory rheumatic diseases (IRD)
hospitalized due to SARS-CoV-2 infection in the Ramón y Cajal Hospital, and to determine the …
hospitalized due to SARS-CoV-2 infection in the Ramón y Cajal Hospital, and to determine the …
Serum Jo-1 autoantibody and isolated arthritis in the antisynthetase syndrome: review of the literature and report of the experience of AENEAS collaborative group
…, F Furini, V Foschi, J Bachiller Corral… - Clinical Reviews in …, 2017 - Springer
Anti-Jo-1 is the most frequently detectable antibody in the antisynthetase syndrome (ASSD),
an autoimmune disease characterized by the occurrence of arthritis, myositis, and interstitial …
an autoimmune disease characterized by the occurrence of arthritis, myositis, and interstitial …
Timing of onset affects arthritis presentation pattern in antisyntethase syndrome
…, A Manfredi, J Bachiller-Corral… - Clinical and …, 2018 - iris.uniroma1.it
To evaluate if the timing of appearance with respect to disease onset may influence the arthritis
presentation pattern in antisynthetase syndrome (ASSD). METHODS: The patients were …
presentation pattern in antisynthetase syndrome (ASSD). METHODS: The patients were …
Impact of Comorbidity on Physical Function in Patients With Ankylosing Spondylitis and Psoriatic Arthritis Attending Rheumatology Clinics: Results From a Cross …
…, C Barbadillo, J Bachiller‐Corral… - Arthritis Care & …, 2020 - Wiley Online Library
Objective To evaluate the impact of comorbidities on physical function in patients with
ankylosing spondylitis (AS) and psoriatic arthritis (PsA). Methods This was a cross‐sectional …
ankylosing spondylitis (AS) and psoriatic arthritis (PsA). Methods This was a cross‐sectional …
Cardiovascular mortality and cardiovascular event rates in patients with inflammatory rheumatic diseases in the CARdiovascular in rheuMAtology (CARMA) …
…, M Romera-Baurés, J Bachiller-Corral… - …, 2021 - academic.oup.com
Objectives To determine cardiovascular (CV) mortality and incidence of the first CV event (CVE)
in patients with chronic inflammatory rheumatic diseases (CIRD) after 5 years of follow-…
in patients with chronic inflammatory rheumatic diseases (CIRD) after 5 years of follow-…